Biocitech Life Science Park Welcomes Chem-X-Infinity and Spectralys Innovation
News Nov 25, 2008
Biocitech, the Paris life science technology park, announces that two new companies, Chem-X-Infinity and Spectralys Innovation, have become the park's 23rd and 24th residents. The new companies bring new strengths in chemistry and consulting to the life science industry.
Chem-X-Infinity sarl is specialized in the automated synthesis of libraries of organic molecules for the pharmaceutical and agrochemical industries. Founded in 2008, this company uses standard medicinal chemistry filters and molecular modeling tools including virtual screening and docking, to identify molecules whose chemical structure appears to be of interest.
Chem-X-Infinity sells from catalog on a semi-exclusive basis, offering to design exclusive focused chemical libraries. Chem-X-Infinity's products offer in vitro biological screening to accelerate the process of finding new active molecules.
"Biocitech is delighted to welcome Chem-X-Infinity and Spectralys Innovation, two companies who boost our activities in chemistry and R&D," said Biocitech CEO, Jacques Lhomel. "The three new arrivals this fall demonstrate our success and our drive for expansion, generating the need to double the area of the park. Expansion work is planned to start at the end of 2009 for completion in 2011."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019